Manuscript TUBI-D-15-01503 for review

"Editorial Office Tumor Biology" <em@editorialmanager.com>

收件人："Shicheng Guo" <scguo@ucsd.edu>

时　间：2015-5-28 7:59:21

附　件：

Dear Prof. Guo,

In view of your expertise I would be very grateful if you could review the following manuscript which has been submitted to Tumor Biology.

Manuscript Number: TUBI-D-15-01503

Title: MicroRNA-138 negatively regulates non-small cell lung cancer cells through the interaction with Cyclin D3

Abstract: Background: Previous studies demonstrate that microRNA-138 (miR-138) is critical in non-small cell lung cancer (NSCLC) regulation. We further explored the molecular mechanism of miR-138 in NSCLC.
Methods: Lentivirus was used to upregulate miR-138 in NSCLC cell lines H460 and SPC-A1 cells. Previously known effects of miR-138 upregulation on NSCLC, proliferation, cell cycle division and cisplatin sensitivity, were assessed. Moreover, previously unknown effect of miR-138 upregulation on NSCLC migration was also examined in H460 and SPC-A1 cells. A new miR-138 downstream target, cyclin D3 (CCND3), was assessed by dual-luciferase reporter assay and qRT-PCR. CCND3 was then ectopically over-expressed in H460 and SPC-A1 cells. The effects of forced overexpression of CCND3 on miR-138 induced NSCLC regulations, were further examined by proliferation, cell cycle, cisplatin sensitivity and migration assays, respectively.
Results: Lentivirus-induced miR-138 upregulation inhibited NSCLC proliferation and cell cycle division, in line with previous findings. Moreover, we found miR-138 upregulation had other anti-tumor effects, such as increasing cisplatin sensitivity and reducing cancer migration, in H460 and SPC-A1 cells. Luciferase assay and qRT-PCR showed CCND3 was directly targeted by miR-138. Forced overexpression of CCND3 in H460 and SPC-A1 cells reversed the anti-tumor effects of miR-138 upregulation on cancer cell growth, cell cycle, cisplatin sensitivity and migration.
Conclusions: Our study revealed novel anti-cancer effects of miR-138 upregulation in NSCLC, as well as its new molecular target of CCND3.

In case you accept to review this submission please click on this link:

http://tubi.edmgr.com/l.asp?i=209521&l=JCXKDMP5

If you do not have time to do this, or do not feel qualified, please click on this link:

http://tubi.edmgr.com/l.asp?i=209522&l=F1BN8IBG

We hope you are willing to review the manuscript. If so, would you be so kind as to return your review to us wit hin 14 days of agreeing to review? Thank you.

You are requested to submit your review online by using
the Editorial Manager system which can be found at:
http://tubi.edmgr.com/. Your username is: SGuo-577 and your password is: guo53465.

IN ORDER TO KEEP DELAYS TO A MINIMUM, PLEASE ACCEPT OR DECLINE THIS ASSIGNMENT ONLINE AS SOON AS POSSIBLE!

If you have any questions, please do not hesitate to contact us. We appreciate your assistance.

With kind regards,
Torgny Ingemar Stigbrand, Ph.D., MD.,Prof